Nintedanib is a drug used to treat respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a tyrosine kinase inhibitor that works by blocking the activity of certain proteins that are involved in the development of fibrosis. Nintedanib is approved by the US Food and Drug Administration (FDA) for the treatment of IPF and SSc-ILD. It is also approved in Europe and other countries for the treatment of IPF. Nintedanib is marketed by Boehringer Ingelheim, a German pharmaceutical company. Other companies involved in the market include Novartis, AstraZeneca, and GlaxoSmithKline. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
